Clinical Study
Serum Asymmetric Dimethylarginine, Nitrate, Vitamin B_{12}, and Homocysteine Levels in Individuals with Pulmonary Embolism

Murat Altuntas¸, Figen Atalay, Murat Can, Remzi Altın, and Meltem Tor

1 Department of Pulmonary Medicine, Faculty of Medicine, Zonguldak Karaelmas University, Zonguldak 67600, Turkey
2 Department of Biochemistry, Faculty of Medicine, Zonguldak Karaelmas University, Zonguldak 67600, Turkey

Correspondence should be addressed to Figen Atalay, dilekdr@hotmail.com

Received 5 March 2011; Revised 6 April 2011; Accepted 1 May 2011

1. Introduction

A pulmonary artery embolism is defined as a partial or complete occlusion of a pulmonary arterial branch. Approximately 70% of cases are caused by pelvic or leg thromboses [1, 2]. Precise figures for the incidence of pulmonary embolism (PTE) are not available. The annual incidence of diagnosed venous thromboembolism (VTE) is 150 to 200 cases per 100,000 population [3]. Considering the unknown number of clinically silent embolisms and the nonspecific clinical presentation, the actual disease frequency is underestimated.

PTE is a severe and potentially fatal disease when the embolism is massive. CTEPH, which develops after the obliteration of the pulmonary vascular bed by repeated and organized PTE, is one of the less frequently seen forms of PTE and is characterized by unexplained dyspnea and a reduction in exercise capacity [4]. CTEPH is defined as symptomatic pulmonary hypertension (mean pulmonary artery pressure (mPAP) >25 mmHg) with persistent lung perfusion defects [5].

CTEPH is a life threatening and debilitating disease affecting up to 5% of survivors of PTE [6]. The disease is underdiagnosed, and its true prevalence is still unclear. It is characterized by intraluminal thrombus organization and fibrotic stenoses or complete obliteration of the pulmonary arteries. Pulmonary embolism, either as single or recurrent episode(s), is believed to be the initiating event, followed by progressive vascular remodeling [7]. CTEPH is a common variation of PTE [8]. Endothelial dysfunction, attributable to the reduced bioavailability of endogenous vasodilator substances such as NO, is believed to play an important role in the pathogenesis of pulmonary hypertension [9, 10]. NO is synthesized in the endothelium from L-arginine by NO synthase (NOS), which is present as either endothelial NOS (eNOS) or inducible NOS (iNOS), representing important vascular isoforms. The most abundant endogenous NOS inhibitor is ADMA [11]. Homocysteine is also associated with endothelial dysfunction [12]. Homocysteine is a sulfhydryl amino acid derived from the metabolic conversion of methionine. This conversion is dependent on vitamins (folic acid, B_{12}, and B_{6}) as cofactors or cosubstrates.
Severe hyperhomocysteinemia (homocystinuria), due to inherited metabolic defects in homocysteine metabolism, is associated with a very high risk of VTE, and treatment with vitamins is associated with a dramatic decrease in the VTE risk [13]. The results of earlier studies have suggested that excess levels of homocysteine lead to increases in ADMA levels and the impairment of endothelial function [12, 14]. It has been hypothesized that the NO, ADMA, and homocysteine levels may provide information about the likelihood of the development of CTEPH in PTE patients. Skoro-Sajer et al. found that increased ADMA plasma levels were present in patients with CTEPH. ADMA levels were correlated with the severity of pulmonary vascular disease, and they decreased after pulmonary endarterectomy [15].

The purpose of our study was to analyze the pre- and posttreatment serum ADMA, NO3, vitamin B12, and homocysteine levels in PTE patients and to evaluate the predictive value of the variables for development of CTEPH.

2. Materials and Methods

2.1. Subjects. The subjects of our study were selected among patients who were admitted to the Zonguldak Karaelmas University Hospital Pulmonary Clinic between March 1, 2009 and December 31, 2009. A total of 100 patients who were diagnosed with PTE were included in the study. The diagnosis of pulmonary embolism was confirmed only when computed tomography angiography (CTPA) showed a pulmonary vascular filling defect or when ventilation-perfusion (V/Q) scintigraphy showed at least two segmental defects without ventilation defects. During the diagnosis period, all the patients underwent echocardiography, and the mean PAPs were measured. Posttreatment echocardiograms were obtained in 50 surviving patients at the end of 3 months. The patients who did not experience a decrease in PAP underwent V/Q scintigraphy to determine if CTEPH had developed.

Patients receiving drugs affecting the homocysteine level (vitamin B6, vitamin B12, folic acid, folic acid, or fenoﬁbrates) or drugs affecting the ADMA level (L-arginine, ACE inhibitors, metformin and thiazolidinediones, estrogens, vitamin D, folic Acid, all-transretinoic acid, or fenoﬁbrates); patients with end-stage liver disease, end-stage renal disease, acute coronary syndrome, severe congestive heart failure, Alzheimer’s disease or preeclampsia; patients in hemorrhagic shock were excluded from the study.

Echocardiography was performed in all patients during the diagnosis period. Pulmonary hypertension was defined as mPAP >25 mmHg. Patients’ ejection fractions (EF) were measured, and the patients with advanced heart failure (EF (%) < 40) were excluded from the study. None of the patients were on anticoagulant therapy for any event at the time of diagnosis. Patients received either low-molecular-weight heparin or enoxaparin at a fixed dose per kilogram of body weight subcutaneously two times per day or unfractionated heparin at an initial bolus dose of 80 IU per kilogram followed by a continuous intravenous infusion at an initial rate of 18 IU per kilogram per hour. The dose was subsequently adjusted so that the activated partial thromboplastin time (aPTT) was two to three times the control value in normal subjects. aPTTs were determined six hours after the start of treatment and whenever a subtherapeutic aPTT was measured after a dose adjustment. Otherwise, the aPTT was tested daily. In each patient, oral anticoagulant therapy was initiated between the first and third days of the initial heparin therapy and was continued for at least three months. The dose was adjusted to achieve an international normalized ratio (INR) of 2.0 to 3.0. Heparin was stopped after 5 days of combined therapy with oral anticoagulant drug when the INR exceeded 2.0. Three of the patients with a diagnosis of acute massive embolism were given heparin and an oral anticoagulant after thrombolytic treatment (tissue plasminogen activator (tPA), 100 mg over 2 hours).

The patients were informed about the study, and the study protocol was approved by our hospital’s ethics committee (date 03/19/2009 and meeting no. 2009/04).

2.2. Samples. At diagnosis and at the end of 3 months of pulmonary embolism therapy, 20 cc antecubital venous blood was drawn from the patients to evaluate biochemical parameters (e.g., the levels of folic acid, vitamin B12, homocysteine, ADMA, and NO3).

2.3. Laboratory Investigations. Biochemical levels (folic acid, vitamin B12) were measured by enzymatic techniques using a DAX 72 autoanalyzer (Bayer Diagnostics Division, Tarrytown, NY, USA). Sera in biochemistry and hemogram tubes were separated by centrifugation in a cooling centrifuge at 3500 × g for 10 minutes for the ADMA, NO2, and homocysteine analyses. They were aliquoted into Eppendorf tubes and stored at −80 °C for ADMA, NO2, and homocysteine measurements. Homocysteine was evaluated using an ELX800 ELISA plaque reader instrument with an axis shield diagnostic ELISA kit (Dundee, UK), and the results were recorded. Homocysteine levels of 5–15 mg/dl were considered normal. For vitamin B12, values of 19–946 pg/mL were considered normal, and for folic acid, values of 4.6–18.7 ng/mL were considered normal. Serum ADMA levels were evaluated with commercial ELISA kits (Immundiagnostik AG, Bensheim, Germany) using an ELX800 ELISA plaque reader instrument. The results were expressed as µmol/L. Because the half-life of NO is very short (10–30 sec.) and measurement is difficult because it is rapidly oxidized and converted into nitrite (NO2) and nitrate (NO3), total nitrate levels were used as a reflection of NO levels. The total serum nitrate measurement was performed by the cadmium reduction method [16].

3. Statistical Analysis

Statistical analysis was done using the SPSS USA (version 13.0) program. The compliance of numerical variables to a normal distribution was assessed using the Kolmogorov-Smirnov test. Definitive statistics were expressed as the mean ± standard deviation for normally distributed data and as the number and percentage for categorical variables. Relationships between categorical variables were assessed by the Chi-Square and Fisher’s Exact tests. Nonparametric data were
**4. Results**

Of 100 patients with PTE diagnosed between March 2009 and December 2009, 36 patients discontinued the study during the followup. Therefore, 64 patients were included in the study. Fifteen patients died during treatment period. The baseline patient characteristics and hemodynamic parameters are summarized in Table 1. Of these 64 patients, 59 (93%) were nonsmokers, 39 (39%) were exsmokers, and 2 (3%) were active smokers. V/Q scintigraphy was performed in 10 of the 50 surviving patients with an elevated PAP determined by control echocardiography at the end of three months of treatment. Perfusion defects were detected in 9 (14%) of the 64 patients, and these patients were considered CTEPH candidates. The patients were classified into two groups: patients with a normal PAP (group I) and patients with a high PAP and/or a moderate to high probability based on V/Q scintigraphy or who died before the end of the 3 months of therapy (group II). Heart failure, renal failure, COPD (chronic obstructive pulmonary disease), and prior malignancy were present in 10 (16%), 5 (8%), 25 (25%), and 13 (20%) of patients, respectively. When the two groups were compared, statistically significant differences were detected with respect to the partial oxygen pressure \( P < 0.001 \), the oxygen saturation \( P < 0.001 \), and the PAP \( P = 0.008 \) (Table 1). There was no statistically significant difference between the two groups with respect to comorbidities. Moreover, there were no statistically significant differences between the two groups in terms of pretreatment ADMA, NO3, or homocysteine levels \( P > 0.05 \). However, vitamin B12 levels were higher in group II (patients with high PAP or who died) compared to group I (patients with normal PAP); this difference was statistically significant \( P = 0.003 \) (Table 2). The posttreatment ADMA, NO3, homocysteine, and vitamin B12 levels were evaluated at the end of the 3 months of therapy. We found that after treatment, the NO3 levels increased \( P < 0.001 \) from initial low levels, and the ADMA \( P < 0.001 \) and vitamin B12 levels decreased significantly \( P < 0.006 \) from initial high levels; the homocysteine levels did not change significantly (Table 3). At the beginning of the treatment period, the patients were classified into four categories according to their arterial pO2 levels as normoxic \( n = 1 \), mildly hypoxic \( n = 34 \), moderately hypoxic \( n = 27 \), or severely hypoxic \( n = 2 \). When mildly and moderately hypoxic patients were compared to severely hypoxic patients in terms of the pretreatment ADMA, NO3, homocysteine, and mPAP levels, only the mPAP was found to be significantly different between the two groups \( P = 0.009 \) (Table 4). High serum homocysteine levels were found in 58% of our patients, and the pre- and posttreatment serum homocysteine and ADMA levels were found to be significantly correlated \( r: 0.300, P: 0.016 \) and \( r: 0.293, P: 0.039 \). Esp. 

**5. Discussion**

The major novel findings of the present study are as follows: (1) In the 4th month of treatment, 14% of acute pulmonary embolism patients still had high PAPs and perfusion defects. (2) Initial high ADMA levels decreased after the treatment, 

---

**Table 1: Parameters at the beginning of the treatment in Group I and Group II.**

|                  | Group I  | Group II | \( P \) |
|------------------|----------|----------|---------|
| Age (years)      | 65.7 ± 13.4 | 70.9 ± 14.1 | 0.148   |
| Sex (female/male)| 20/20    | 13/11    | 0.949   |
| Partial oxygen pressure (mmHg) | 62.1 ± 7.4 | 54.1 ± 9.3 | <0.001* |
| Oxygen saturation (%) | 92.8 ± 3.2 | 86.8 ± 6.2 | <0.001* |
| Mean PAP (mmHg)  | 39.0 ± 9.6 | 50.8 ± 21.8 | 0.008*  |

\* Group I: Patients with normal pulmonary artery pressure at the end of three months of treatment.
\*

**Table 2: Pretreatment ADMA, NO3, homocysteine, and vitamin B12 levels in patients with normal pulmonary pressure (Group I) and patients with high pulmonary pressure or who died (Group II).**

|                  | Group I  | Group II | \( P \) |
|------------------|----------|----------|---------|
| ADMA (µmol/L)    | 0.63 ± 0.19 | 0.58 ± 0.26 | 0.399   |
| NO3 (µmol/L)     | 33.8 ± 2.4 | 33.8 ± 2.1 | 0.978   |
| Homocysteine (mg/dl) | 19.2 ± 8.8 | 17.1 ± 8.1 | 0.358   |
| Vitamin B12 (pg/dl) | 380.5 ± 244.7 | 649.3 ± 463.9 | 0.003*  |
Table 3: ADMA, NO$_3$, homocysteine, and vitamin B$_{12}$ levels in patients (before and after 3 months of anticoagulant therapy).

|                     | Before therapy $n = 50$ | After 3 months of therapy $n = 50$ | $P$  |
|---------------------|--------------------------|-----------------------------------|------|
| ADMA ($\mu$mol/L)   | $0.64 \pm 0.19$          | $0.49 \pm 0.16$                  | $<0.001^*$ |
| NO$_3$ ($\mu$mol/L) | $33.7 \pm 2.3$           | $41.5 \pm 4.4$                   | $<0.001^*$ |
| Homocysteine (mg/dl)| $18.4 \pm 8.3$           | $19.3 \pm 9.9$                   | 0.519 |
| Vitamin B$_{12}$ (pg/dl)| $443.3 \pm 300.7$            | $355.6 \pm 215.9$               | $0.006^*$ |

Table 4: Pretreatment ADMA, NO$_3$, homocysteine and mean PAP levels according to the patients’ hypoxia levels.

| Level hypoxia | n | Mean ± standard deviation | $P$  |
|---------------|---|---------------------------|------|
| ADMA ($\mu$mol/L) | Mild | 34 | $0.62 \pm 0.22$ | 0.709 |
|               | Moderate-severe | 29 | $0.60 \pm 0.23$ | |
| NO$_3$ ($\mu$mol/L) | Mild | 34 | $33.8 \pm 2.1$ | 0.920 |
|               | Moderate-severe | 29 | $33.8 \pm 2.4$ | |
| Homocysteine (mg/dl) | Mild | 34 | $18.6 \pm 9.2$ | 0.964 |
|               | Moderate-severe | 29 | $18.5 \pm 7.9$ | |
| Mean PAP (mmHg) | Mild | 34 | $38.1 \pm 10.9$ | $0.009^*$ |
|               | Moderate-severe | 29 | $49.3 \pm 19.4$ | |

whereas NO$_3$ levels increased. Additionally, the vitamin B$_{12}$ levels decreased with anticoagulant treatment. (3) Pretreatment hypoxia was found to be a poor prognostic factor for PTE. (4) In the poor prognosis group, the vitamin B$_{12}$ levels were high, but no statistically significant difference was found between the ADMA, NO$_3$, and homocysteine levels.

There has recently been increasing interest in asymmetric dimethylarginine (ADMA) as a marker and potential mediator of endothelial dysfunction in pulmonary vascular disease patients and as a potent competitive inhibitor of NOS [17]. ADMA is derived from the catabolism of proteins containing methylated arginine residues. Higher ADMA concentrations have been measured in many cardiovascular and metabolic diseases, such as coronary artery disease, congestive heart failure, peripheral arterial occlusive disease, hypercholesterolemia, hypertension, and diabetes mellitus [18, 19]. ADMA has not been measured previously in acute pulmonary embolism patients. In our study, there were no statistically significant differences between the two groups with respect to the pretreatment ADMA and NO$_3$ levels. In both groups, the NO$_3$ levels increased, and the ADMA and vitamin B$_{12}$ levels decreased with treatment.

It is not known clearly how the treatment acts on the ADMA and NO levels. It was concluded that these effects might be the results of compensatory mechanisms related to improvement in hypoxia and/or prolongation of period. Changes in the vessel wall and the coagulation system and chronic hypoxia are of value in predicting CTEPH development [20–22]. Fifteen of our patients died during treatment. We observed that 71% of cases in group II had moderate to severe hypoxia. We concluded that persistent high PAP and hypoxemia, compared with pretreatment values, were found to be significant parameters predicting poor prognosis.

CTEPH was recently documented to complicate 3.8% of acute pulmonary embolic events [3, 4]. However, there may be many unreported cases, so the actual number of cases may be higher. At the end of three months of treatment and at the 12-month followup, 9% and 5% of acute pulmonary embolism patients, respectively, showed high PAP and persistent perfusion defect in our study.

ADMA has been evaluated in several different classes of pulmonary hypertension. Plasma levels were found to be significantly higher in idiopathic pulmonary arterial hypertension patients than in healthy matched controls [23]. In a recent study of 135 patients diagnosed with CTEPH, the plasma ADMA levels were measured at the time of right heart catheterization and was remeasured in patients who underwent pulmonary endarterectomy. The ADMA level was significantly elevated in patients compared with controls [15]. However, in our study, we could not find any significant difference in the plasma levels of NO$_3$ and ADMA with respect to mPAP. The variable conclusions of the published studies to date seem to be related to comparing the ADMA levels in the disease state with healthy controls. Similar to our study, other authors have reported decreased levels of ADMA after treatment (endarterectomy). In addition, the measurement method of ADMA may vary. One of the reasons could be the use of the more sensitive high-performance liquid chromatography (HPLC) analysis method by other authors instead of the ELISA method that was used. In recent years, ELISA has been reported to be compatible with HPLC, but many studies have demonstrated that the HPLC method has better sensitivity and selectivity [24].

It has been reported that elevated homocysteine levels are associated with elevated ADMA levels. Both homocysteine and ADMA are thought to mediate their adverse vascular effects by impairing endothelial nitric oxide-dependent functions. Previous studies have shown that serum ADMA levels were positively correlated with serum homocysteine levels, as shown in our study [25, 26]. Our study showed that
the pre- and posttreatment serum homocysteine and ADMA levels were significantly correlated.

There is a relationship among increased plasma homocysteine, folic acid, and vitamin B₁₂ levels and premature arterial disease [12, 13]. Böger et al. [12] observed a correlation between plasma ADMA and homocysteine levels in monkeys with hyperhomocysteinemia. Folic acid, vitamin B₆, and vitamin B₁₂ levels are the significant determinants of homocysteine levels [27]. Serum homocysteine levels were high in 58% of our patients. We found high B₁₂ vitamin levels in the poor prognosis group, and the serum levels were decreased after treatment.

In conclusion, the lack of a difference in the pretreatment ADMA and NO₃ levels between patients with normal and high PAPs, together with the significant decrease in the ADMA level and the increase in the NO₃ level after the treatment, suggests that these parameters are not predictive of the development of CTEPH.

References

[1] V. F. Tapson, “Acute pulmonary embolism,” New England Journal of Medicine, vol. 358, no. 10, pp. 1037–1052, 2008.
[2] A. Torbicki, A. Perrier, S. Konstantinides et al., “Guidelines on the diagnosis and management of acute pulmonary embolism: the task force for the diagnosis and management of acute pulmonary embolism of the European Society of Cardiology (ESC),” European Heart Journal, vol. 29, pp. 2276–2315, 2008.
[3] S. Z. Goldhaber, “Pulmonary embolism,” Lancet, vol. 363, no. 9417, pp. 1295–1305, 2004.
[4] V. Pengo, A. W. Lensing, M. H. Prins et al., “Incidence of chronic thromboembolic pulmonary hypertension after pulmonary embolism,” New England Journal of Medicine, vol. 35, pp. 2257–2264, 2004.
[5] A. M. Keogh, E. Mayer, R. L. Benza et al., “Interventional and surgical modalities of treatment in pulmonary hypertension,” Journal of the American College of Cardiology, vol. 54, supplement 1, pp. S67–S77, 2009.
[6] J. Pepke-Zaba, “Diagnostic testing to guide the management of chronic thromboembolic pulmonary hypertension: state of the art,” European Respiratory Review, vol. 19, no. 115, pp. 55–58, 2010.
[7] M. M. Hoeper, E. Mayer, G. Simonneau, and L. J. Rubin, “Chronic thromboembolic pulmonary hypertension,” Circulation, vol. 113, no. 16, pp. 2011–2020, 2006.
[8] I. M. Lang, “Chronic thromboembolic pulmonary hypertension—not so rare after all,” New England Journal of Medicine, vol. 350, no. 22, pp. 2236–2238, 2004.
[9] A. T. Dinh-Xuan, T. W. Higenbottam, C. A. Clelland et al., “Impairment of endothelium-dependent pulmonary-artery relaxation in chronic obstructive lung disease,” New England Journal of Medicine, vol. 324, no. 22, pp. 1539–1547, 1991.
[10] C. J. Cooper, M. J. Landzberg, T. J. Anderson et al., “Role of nitric oxide in the local regulation of pulmonary vascular resistance in humans,” Circulation, vol. 93, no. 2, pp. 266–271, 1996.
[11] R. A. Dweik, “The lung in the balance: arginine, methylated arginines, and nitric oxide,” American Journal of Physiology—Lung Cellular and Molecular Physiology, vol. 292, no. 1, pp. L15–L17, 2006.
[12] R. H. Böger, S. M. Bode-Böger, K. Sydow, D. D. Heistad, and S. R. Lentz, “Plasma concentration of asymmetric dimethylarginine, an endogenous inhibitor of nitric oxide synthase, is elevated in monkeys with hyperhomocyst(e)inemia or hypercholesterolemia,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 20, no. 6, pp. 1557–1564, 2000.
[13] J. G. Ray, “Meta-analysis of hyperhomocysteinemia as a risk factor for deep-vein thrombosis,” New England Journal of Medicine, vol. 334, no. 12, pp. 759–762, 1996.
[14] K. Robinson, K. Arheart, H. Refsum et al., “European COMAC Group. Low circulating folate and vitamin B₆ concentrations: risk factors for stroke, peripheral vascular disease, and coronary artery disease,” Circulation, vol. 97, pp. 437–443, 1998.
[15] N. Skoro-Sajer, F. Mittermayer, A. Panzenboeck et al., “Asymmetric dimethylarginine is increased in chronic thromboembolic pulmonary hypertension,” American Journal of Respiratory and Critical Care Medicine, vol. 176, no. 11, pp. 1154–1160, 2007.
[16] N. K. Cortas and N. W. Wakis, “Determination of inorganic nitrate in serum and Urine by a kinetic cadmium-reduction method,” Clinical Chemistry, vol. 3618, pp. 1440–1443, 1990.
[17] J. P. Cooke, “A novel mechanism for pulmonary arterial hypertension,” Circulation, vol. 108, no. 12, pp. 1420–1421, 2003.
[18] M. C. Stühlinger, P. S. Tsao, J. H. Her, M. Kimoto, R. F. Balint, and J. P. Cooke, “Homocysteine impairs the nitric oxide synthase pathway: role of asymmetric dimethylarginine,” Circulation, vol. 104, no. 21, pp. 2569–2575, 2001.
[19] G. Warwick, P. S. Thomas, and D. H. Yates, “Biomarkers in pulmonary hypertension,” European Respiratory Journal, vol. 32, no. 2, pp. 503–512, 2008.
[20] M. Meysman, M. Diltoer, H. D. Raeve, I. Monsieur, and L. Huyghens, “Chronic thromboembolic pulmonary hypertension and vascular transformation of the lymph node sinuses,” European Respiratory Journal, vol. 10, no. 5, pp. 1191–1193, 1997.
[21] R. Sacks, C. V. Remillard, N. Agan, W. R. Auger, P. A. Thistlethwaite, and J. X. J. Yuan, “Molecular biology of chronic thromboembolic pulmonary hypertension,” Seminars in Thoracic and Cardiovascular Surgery, vol. 18, no. 3, pp. 265–276, 2006.
[22] I. Lang and K. Kerr, “Risk factors for chronic thromboembolic pulmonary hypertension,” Proceedings of the American Thoracic Society, vol. 3, no. 7, pp. 568–570, 2006.
[23] J. T. Kielstein, S. M. Bode-Böger, G. Hesse et al., “Asymmetric dimethylarginine in idiopathic pulmonary arterial hypertension,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 25, no. 7, pp. 1414–1418, 2005.
[24] P. Valtonen, J. Karppi, K. Nyyssönen, V. P. Valkonen, T. Halonen, and K. Punnonen, “Comparison of HPLC method and commercial ELISA assay for asymmetric dimethylarginine (ADMA) determination in human serum,” Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, vol. 828, no. 1-2, pp. 97–102, 2005.
[25] S. R. Lentz, N. R. Rodinov, and D. Sanjana, “Hyperhomocysteinemia, endothelial dysfunction, and cardiovascular risk: the potential role of ADMA,” Atherosclerosis, vol. 4, pp. 61–65, 2003.
[26] P. Vallance and J. Leiper, “Cardiovascular biology of the asymmetric dimethylarginine: dimethylarginine dimethylaminohydrolase pathway,” *Arteriosclerosis, Thrombosis, and Vascular Biology*, vol. 24, no. 6, pp. 1023–1030, 2004.

[27] Y. Song, N. R. Cook, C. M. Albert, M. Van Denburgh, and J. E. Manson, “Effect of homocysteine-lowering treatment with folic acid and B vitamins on risk of type 2 diabetes in women: a randomized, controlled trial,” *Diabetes*, vol. 58, no. 8, pp. 1921–1928, 2009.